ArticleScientific reports2025
Towards antibody-based immunotherapy development for platinum-resistant high-grade serous ovarian cancer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
Abstract
Epithelial ovarian cancer is the sixth most common malignant neoplasm in women and the leading cause of death from gynecological malignancies in the Western World. The five-year survival rate is 45–48% because of the high frequency of late-stage diagnoses and the development of chemo-resistant disease. To assess the potential of antibodies and complement to kill platinum (Pt)-resistant and Pt-sensitive cell lines, antibodies S2 and Yth53.1 were tested at varying concentrations using high-grade serous ovarian cancer (HGSOC) cells. Cell lysis was quantified after 60 minutes using the impermeant dyes 7-Aminoactinomycin D and Annexin V. The cytotoxic effect of S2 was demonstrated through the activation of the complement and Yth53.1 monoclonal antibody neutralized the membrane attack complex (MAC) inhibitor CD59 and allowed assembly of the MAC. In contrast to Pt-based therapy, we found no evidence that chemo-resistance plays an important role when considering the antibody based therapy for Pt-resistant HGSOC cell lines. Significant killing efficiencies were achieved using antibodies against breast cancer cells (S2) and antibody against CD59 (Yht53.1) regardless whether the cell lines HGSOC (OVCAR-3, OVCAR-8) or CRISPR-Cas9 BRCA2 deleted OVCAR-4 were homologous recombination (HR) deficient or proficient, Pt sensitive or resistant. This work shows a potential towards antibody-based therapy development for Pt-resistant HGSOC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.